Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Reside in a country where there are ongoing Lilly-sponsored clinical trials (currently this is only the United States)
Present within 10 days of symptom onset
Have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by reverse transcription polymerase chain reaction (RT-PCR) within the last three days
Participants greater than or equal to (≥) 65 years of age OR
Participants ≥ 12 years of age who weigh at least 40 kilograms AND have at least one of the following:
Chronic kidney disease
Chronic obstructive pulmonary disease (COPD) or other chronic lung disease
Immunocompromised state (weakened immune system or on immunomodulatory medications)
Obesity (body mass index [BMI] of 35 or higher)
Serious heart conditions such as heart failure, coronary artery disease or cardiomyopathies
Sickle cell disease
Diabetes mellitus (Types 1 or 2)
Require hospitalization greater than (>) 24 hours or hospice care. Residents in long term care or skilled nursing facilities that meet the inclusion criteria and are not on mechanical ventilation will be considered
Bamlanivimab should not be used in patients hospitalized with severe COVID-19 respiratory disease